GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases. They leverage their deep understanding of carbohydrate biology to design small molecule drugs called glycomimetics, aiming to improve patient outcomes. Their lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed/refractory AML and has received Breakthrough Therapy and Fast Track designations from the FDA. The company collaborates with academic, governmental, and pharmaceutical partners to advance their programs.
Industries
Nr. of Employees
medium (51-250)
GlycoMimetics, Inc.
9708 Medical Center Drive, Rockville, MD 20850
Products
E-selectin antagonist (intravenous; pivotal Phase 3 for relapsed/refractory AML)
Investigational, first-in-class small-molecule E-selectin antagonist developed to block E-selectin–ligand interactions in the bone marrow microenvironment and sensitize leukemia cells to chemotherapy; progressed into pivotal Phase 3 and Phase 2/3 studies.
Subcutaneous E-selectin antagonist (preclinical/Phase 1 for sickle cell disease)
Second-generation potent E-selectin antagonist optimized for subcutaneous administration with preclinical data showing full bioavailability and a Phase 1 clinical study clearance for development in sickle cell disease to address vaso-occlusive crises.
Oral Galectin-3 antagonist (preclinical lead selected)
Orally bioavailable small-molecule antagonists of Galectin-3 designed to inhibit galectin-mediated inflammation, fibrosis, and tumor-supportive immune responses; a preclinical lead was selected for further development.
E-selectin antagonist (intravenous; pivotal Phase 3 for relapsed/refractory AML)
Investigational, first-in-class small-molecule E-selectin antagonist developed to block E-selectin–ligand interactions in the bone marrow microenvironment and sensitize leukemia cells to chemotherapy; progressed into pivotal Phase 3 and Phase 2/3 studies.
Subcutaneous E-selectin antagonist (preclinical/Phase 1 for sickle cell disease)
Second-generation potent E-selectin antagonist optimized for subcutaneous administration with preclinical data showing full bioavailability and a Phase 1 clinical study clearance for development in sickle cell disease to address vaso-occlusive crises.
Oral Galectin-3 antagonist (preclinical lead selected)
Orally bioavailable small-molecule antagonists of Galectin-3 designed to inhibit galectin-mediated inflammation, fibrosis, and tumor-supportive immune responses; a preclinical lead was selected for further development.
Services
Negotiate and execute collaboration and license agreements for regional development and commercialization; manage partner responsibilities for clinical development and commercialization in defined territories.
Provide investigational drug product and financial or data analysis support for cooperative group trials, investigator-initiated trials, and collaborative clinical studies.
Partnerships with academic and research institutes to perform mechanistic and preclinical studies that inform clinical development strategies.
Negotiate and execute collaboration and license agreements for regional development and commercialization; manage partner responsibilities for clinical development and commercialization in defined territories.
Provide investigational drug product and financial or data analysis support for cooperative group trials, investigator-initiated trials, and collaborative clinical studies.
Partnerships with academic and research institutes to perform mechanistic and preclinical studies that inform clinical development strategies.
Expertise Areas
- Glycobiology-driven small-molecule drug discovery
- E-selectin-targeted therapeutic development
- Clinical trial management and adaptive trial design
- Oncology drug development (acute myeloid leukemia)
Key Technologies
- Glycobiology
- Glycomimetic small-molecule chemistry
- E-selectin antagonism
- Galectin-3 antagonism
News & Updates
On June 5, 2025, stockholders approved the proposed merger with Crescent Biopharma.
On November 6, 2024, new clinical data for uproleselan was announced to be presented at the ASH Annual Meeting.
On October 29, 2024, GlycoMimetics announced entering into an acquisition agreement with Crescent Biopharma.
On October 29, 2024, it was announced that the Phase 2/3 study of uproleselan did not meet its primary endpoint.
On June 5, 2025, stockholders approved the proposed merger with Crescent Biopharma.
On November 6, 2024, new clinical data for uproleselan was announced to be presented at the ASH Annual Meeting.
On October 29, 2024, GlycoMimetics announced entering into an acquisition agreement with Crescent Biopharma.
On October 29, 2024, it was announced that the Phase 2/3 study of uproleselan did not meet its primary endpoint.